 |
|
- Clinical and Commercial SolutionsCell Therapies Pty Ltd brings world-best research and science together with astute commercial operations
- Mesoblast Applies For TGA LicenceMesoblast to Apply for Regulatory Approval of its Bone Fracture Repair Products
- Cell Therapies P/L Secures NCRIS Subsidies for its ClientsResearch Infrastructure Support Services (RISS) announced that Cell Therapies (CT) has been awarded subsidies of up to 50% for eligible expenditures being incurred by three clients.
- Research GrantA team at Peter MacCallum Cancer Centre recently received a Grant from the National Medical Health Research Council (NHMRC) of Australia.
- New Lab Helps Translate ResearchA new lab within The Peter MacCallum Cancer Centre will allow seamless translation from research to full cGMP compliance and clinical application.
Research Infrastructure Support Services (RISS) announced that Cell Therapies (CT) has been awarded subsidies of up to 50% for eligible expenditures being incurred by three clients.
Dec/2008
CT also received a $50,000 subsidy for the maintenance of its own TGA license.
These subsidies are directed towards the establishment and maintenance of research infrastructure for cGMP compliant processing of human cells and tissue for transplantation. RISS administers these subsidies under the Federal Government's NCRIS scheme. For more information please see www.risltd.com and. www.ncris.innovation.gov.au.
--------------------------------------------------------------------------------
Cell Therapies Pty Ltd ABN 100 285 916